WO2009076983A3 - Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof - Google Patents

Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof Download PDF

Info

Publication number
WO2009076983A3
WO2009076983A3 PCT/EP2007/011047 EP2007011047W WO2009076983A3 WO 2009076983 A3 WO2009076983 A3 WO 2009076983A3 EP 2007011047 W EP2007011047 W EP 2007011047W WO 2009076983 A3 WO2009076983 A3 WO 2009076983A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
dopamine agonist
pharmaceutical composition
composition containing
containing non
Prior art date
Application number
PCT/EP2007/011047
Other languages
French (fr)
Other versions
WO2009076983A2 (en
Inventor
Evangelos Karavas
Efthimios Koutris
Eleni Stathaki
Vicky Samara
Anastasia Kalaskani
Dimitrios Bikiaris
Original Assignee
Pharmathen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen S.A. filed Critical Pharmathen S.A.
Priority to PCT/EP2007/011047 priority Critical patent/WO2009076983A2/en
Priority to EP07856784A priority patent/EP2227224A2/en
Publication of WO2009076983A2 publication Critical patent/WO2009076983A2/en
Publication of WO2009076983A3 publication Critical patent/WO2009076983A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a non-ergoline dopamine agonist or a pharmaceutical acceptable salt thereof, and especially Ropinirole or pharmaceutical acceptable salt thereof, in combination with an amino acid, as an antioxidant, and a process for the preparation thereof.
PCT/EP2007/011047 2007-12-17 2007-12-17 Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof WO2009076983A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/EP2007/011047 WO2009076983A2 (en) 2007-12-17 2007-12-17 Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof
EP07856784A EP2227224A2 (en) 2007-12-17 2007-12-17 Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2007/011047 WO2009076983A2 (en) 2007-12-17 2007-12-17 Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof

Publications (2)

Publication Number Publication Date
WO2009076983A2 WO2009076983A2 (en) 2009-06-25
WO2009076983A3 true WO2009076983A3 (en) 2009-11-12

Family

ID=39099786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/011047 WO2009076983A2 (en) 2007-12-17 2007-12-17 Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof

Country Status (2)

Country Link
EP (1) EP2227224A2 (en)
WO (1) WO2009076983A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
WO2002049608A1 (en) * 2000-12-21 2002-06-27 Par Pharmaceutical Inc. Cabergoline pharmaceutical compositions and methods of use thereof
US20030119875A1 (en) * 2000-05-08 2003-06-26 Bashore Fadia Najjar Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
WO2006099946A1 (en) * 2005-03-24 2006-09-28 Neurobiotec Gmbh Transdermal therapeutic system
US20070190130A1 (en) * 2006-02-16 2007-08-16 Mark William A Protein hydrolysate excipients
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
US20030119875A1 (en) * 2000-05-08 2003-06-26 Bashore Fadia Najjar Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
WO2002049608A1 (en) * 2000-12-21 2002-06-27 Par Pharmaceutical Inc. Cabergoline pharmaceutical compositions and methods of use thereof
WO2006099946A1 (en) * 2005-03-24 2006-09-28 Neurobiotec Gmbh Transdermal therapeutic system
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20070190130A1 (en) * 2006-02-16 2007-08-16 Mark William A Protein hydrolysate excipients

Also Published As

Publication number Publication date
WO2009076983A2 (en) 2009-06-25
EP2227224A2 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2011124953A3 (en) Controlled release pharmaceutical compositions of tapentadol
WO2008135527A3 (en) Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
TW200621317A (en) Pharmaceutical composition
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
IL194871A (en) Iap bir domain binding compound, an intermediate compound, process for producing the compound, method for preparation of a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it and use of the compound for the manufacture of a medicament
IL208203A (en) 2,3-dihydro-pyrido-1,4-oxazine and 2,3-dihydro-4-oxa-1,9-diazaphenanthrene derivatives, processes for their preparation and pharmaceutical compositions comprising them
TN2010000022A1 (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
WO2008113901A3 (en) Composition with controlled release of levetiracetam and method for preparing same
WO2007113202A8 (en) Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists
WO2010049449A3 (en) Novel salts of sunitinib
IL212966A (en) Substituted pyrazol-1-yl-methyl-cyclohexyl-methoxy acetic acid compounds, pharmaceutical compositions comprising them, use of the compounds in the preparation of medicaments and the compounds for use in a method of treatment
UA96622C2 (en) Solid dosage forms comprising aliskiren obtained by solvent-free granulation process
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2008079963A3 (en) Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients
WO2010029571A3 (en) Modified release ramipril compositions and uses thereof
JO3239B1 (en) Galenical Formulations of Organic Compounds
WO2009136884A3 (en) Metformin-pioglitazone formulation with antihyperglycemic effects
WO2009076983A3 (en) Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof
WO2007110765A3 (en) Processes for the preparation of octreotide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07856784

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007856784

Country of ref document: EP